Vistide

Vistide is an antiviral drug used in the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It is a nucleoside analogue, which interferes with the replication of viral DNA. Vistide is administered by intravenous infusion.

History

Vistide was developed by Gilead Sciences, a biopharmaceutical company based in the United States. It was approved by the Food and Drug Administration (FDA) in June 1996 for the treatment of CMV retinitis in patients with AIDS.

Mechanism of Action

Vistide works by inhibiting the replication of viral DNA. It is a nucleoside analogue, which means it mimics the structure of one of the nucleosides that make up DNA. When the virus attempts to replicate its DNA, it incorporates the Vistide molecule instead of the normal nucleoside, which disrupts the replication process.

Side Effects

Like all drugs, Vistide can cause side effects. The most common side effects include nausea, vomiting, and diarrhea. More serious side effects can include kidney damage, low white blood cell count, and anemia. Patients should be closely monitored while receiving Vistide treatment.

See Also

• Antiviral drug
• Cytomegalovirus (CMV)
• AIDS
• Gilead Sciences
• Food and Drug Administration (FDA)

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian